Hypoactive sexual desire disorder (HSDD) treatment market in LATAM women: will reach $170 million by 2027 | CAGR of 3.8%

Hypoactive sexual desire disorder (HSDD) treatment market in LATAM women: will reach $170 million by 2027 | CAGR of 3.8% latam hypoactive sexual desire

The demand for treatments for hyposexual desire disorder is increasing, due to the increased prevalence of lifestyle-related illnesses such as stress and depression.

PORTLAND, OREGON, UNITED STATES, August 29, 2022 /EINPresswire.com/ — Hypoactive sexual desire disorder (HSDD) It is the most common sexual disorder in women of all ages, but it is also one of the most difficult to treat. It is the most common type of sexual dysfunction in women. HSDD is primarily associated with hyperfunctional inhibition and hypofunctional arousal regulated by neuromodulators in the brain. In addition, several physical conditions are also linked to HSDD, including anxiety, depression, diabetes, urinary incontinence, and multiple sclerosis. Your treatment includes psychotherapy or pharmacotherapy. Psychotherapy uses cognitive behavioral therapy, which offers counseling sessions with a sex therapist, while pharmacotherapy includes treatment with many medications, including buspirone, bremelanotide, bupropion, flibanserin, and others.

♦ Download a free sample report here:
https://www.alliedmarketresearch.com/request-sample/7952

The Female Hypoactive Sexual Desire Disorder Treatment market size in LATAM was $131 million in 2019 and is expected to reach $170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Main key players:

AUROBINDO PHARMA,
BRISTOL-MYERS SQUIBB COMPANY,
GLAXOSMITHKLINE PLC (GSK),
MYLAN N.V.,
NOVARTIS INTERNATIONAL AG,
PALATIN TECHNOLOGIES, INC.,
SPROUT PHARMACEUTICALS, INC.,
SUN PHARMACEUTICAL INDUSTRIES LIMITED,
TEVA PHARMACEUTICAL INDUSTRIES LTD. (GENERIC ACTAVIS),
ZYDUS CADILA

The use of products for the treatment of hypoactive sexual desire disorder (HSDD) in women is expected to experience significant growth, due to the increased use of medications that induce the hypoactive sexual desire disorder state and the increase in the number of surgical procedures leading to sexual dysfunction. . Additionally, the rise in prevalence of hypoactive sexual desire disorder has led to an increase in demand for new treatment options, which is expected to drive market growth during the forecast period.

See also  No female drivers in the Indy 500 for the second time in three years

The presence of drugs in development offers a lucrative opportunity for the market for the treatment of hypoactive sexual desire disorder in LATAM women. Major factors hindering market growth include lack of awareness related to hypoactive sexual desire disorder, leading to limited diagnosis and treatment. For example, there is a lack of public education on sexual health issues in many Latin American countries, such as Brazil and Guyana.

♦ For purchase inquiry:
https://www.alliedmarketresearch.com/purchase-inquiry/7952

Table of Contents:

CHAPTER 1 INTRODUCTION

1.1.Description of the report
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key Study Findings
2.2.CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1.Definition and scope of the market
3.2. key findings

3.2.1.Main winning strategies
3.2.2.Main investment pockets

3.3. Key Forces Shaping the Latin American Women Hypoactive Sexual Desire Disorder Treatment Industry/Market
3.4.Positioning of the best players, 2019
3.5.Annual expenditure, 2019
3.6. Market dynamics

By country, Argentina is expected to show the fastest growth during the forecast period. This is attributed to factors such as increased healthcare infrastructure, increased healthcare spending, and increased awareness related to hypoactive sexual desire disorder.

♦ Report Customization Request:
https://www.alliedmarketresearch.com/request-for-customization/7952

Key study findings:

By treatment type, in terms of value, the bupropion segment dominated the market in 2019 and is anticipated to maintain its dominance throughout the forecast period

By sales channel, the clinic segment is anticipated to grow with the highest CAGR throughout the forecast period.

By treatment type, the bupropion segment accounted for more than half of the market share in 2019.

See also  100 Influential Black Women in Sports: WNBA Star Skylar Diggins-Smith

By country, Argentina is anticipated to grow at the highest rate during the analysis period.

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business consulting wing of Allied Analytics LLP headquartered in Portland, Oregon. Allied Market Research provides global companies as well as small and medium sized businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions”. AMR has a specific vision to provide business information and consulting to help its clients make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services in 11 industry verticals, including life sciences, consumer goods, materials and chemicals, construction and manufacturing, food and beverage, energy and power, semiconductors and electronics, automotive and transportation, ICT and media. , aerospace and defense, and BFSI.

We maintain professional corporate relationships with various companies and this helps us extract market data that helps us generate accurate research data tables and confirms the utmost accuracy in our market forecast. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high data quality and assist clients in every way possible to achieve success. Each and every one of the data presented in the reports published by us is extracted through primary interviews with senior officials of the main companies of the domain in question. Our secondary data acquisition methodology includes in-depth online and offline research and discussions with industry professionals and expert analysts.

David Correa
Allied Analysis LLP
+1 800-792-5285
email us here
Visit us on social networks:
Facebook
Twitter
LinkedIn

See also  Vogue editor Anna Wintour's historic morning show lowered her guard

Hypoactive sexual desire disorder (HSDD) treatment market in LATAM women: will reach $170 million by 2027 | CAGR of 3.8% article